Vaccines could soon be given by sending plasters in the post, effectively spelling the end of the childhood jab. A landmark trial found the patches — which painlessly penetrate the skin — were ...

Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology is currently being evaluated in a phase 1 clinical study of the first needle-free COVID-19 vaccine, having demonstrated ...

Audicana and colleagues evaluated tolerance to thimerosal-containing vaccines in 125 patients sensitized to mercury derivatives and/or thimerosal. [23] Patch-test results in this patient ...

PopVax is developing this vaccine in partnership with Germany’s LTS Lohmann Therapie-Systeme AG (LTS), a leading player in transdermal drug delivery. The Patch Forward Prize is a multi-stage $50 ...

The selection by BARDA recognizes Vaxxas’ significant advancements towards commercializing its proprietary high-density microarray patch (HD-MAP) for vaccine delivery, including completion of ...

Vaxxas and CEPI advance US$ 4.8 million programme for needle-free thermostable mRNA vaccines: Cambridge, Massachusetts Friday, January 24, 2025, 14:00 Hrs [IST] Vaxxas, a clinical ...

Clinical-stage Australian biotechnology company Vaxxas will receive $3.2 million from the US Biomedical Advanced Research and ...

In animal studies, this simple technique induces robust systemic and mucosal antibodies against vaccine antigens. Here, we demonstrate safe application of a patch containing heat-labile ...

This project adds one of the most advanced vaccine patch developers to the CEPI portfolio, as well as CastleVax’s new rapid response platform.” A commitment to equitable access CEPI and Micron ...

[30] Patch testing with the whole vaccine, as well as with its individual components in standardized concentrations and vehicles, was performed on the skin after resolution of the reaction.